Saturday 17 October 2026
Export CLOV’s income statement to Excel — free account
Clover Health Investments, Corp.
CLOV Healthcare Healthcare Plans
Clover Health Investments, Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 40.3% from fiscal 2024. In the quarter to June 2026, revenue grew 55.6%, EPS grew 350.0% and free cash flow grew 406.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
4.48
0.20
−4.27%
Follow CLOV
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.88 | 0.63 | 0.42 | 1.11 | |
P/FCF ratio |
0.00 | 0.00 | 16.85 | 37.01 | |
P/Operating CF |
129.64 | (17.65) | 8.52 | 109.05 | |
P/B ratio |
4.60 | 3.90 | 2.71 | 7.30 | |
Price to Tangible BV |
4.64 | 3.94 | 2.73 | 7.36 | |
EV/Sales |
0.78 | 0.57 | 0.33 | 1.02 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(16.40) | (16.50) | 12.87 | 32.78 | |
EV/FCF |
(16.07) | (16.01) | 13.51 | 34.03 | |
Quick Ratio |
1.35 | 1.03 | 0.82 | 0.98 | |
Current Ratio |
1.71 | 1.47 | 1.33 | 1.50 | |
Net Debt/EBITDA |
8.32 | 2.43 | (7.43) | (8.64) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
2.93 | 3.43 | 3.45 | 3.82 | |
Operating CF/Net income |
(0.50) | 1.38 | 3.95 | 0.90 | |
Capex/Depreciation |
(69.20) | 7.37 | (11.54) | (5.01) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
19.56% | 25.24% | 17.58% | 16.74% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.26% | 5.11% | 1.64% | 1.22% | |
Graham Net Nets |
0.07 | 0.06 | 0.10 | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.68%) | (7.34%) | (6.82%) | (0.95%) | |
Free Cash Flow Yield |
(5.51%) | (5.73%) | 5.93% | 2.70% | |
Revenue per Share |
0.97 | 0.95 | 1.43 | 1.42 | |
Operating CF per Share |
0.02 | (0.13) | 0.21 | 0.05 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.02 | (0.13) | 0.21 | 0.05 | |
Cash per Share |
0.40 | 0.23 | 0.39 | 0.46 | |
Shareholders Equity per Share |
0.66 | 0.60 | 0.65 | 0.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.66 | 0.60 | 0.65 | 0.72 | |
Free Cash Flow |
11.41 | (68.75) | 107.04 | 24.51 | |
Working Capital |
137.47 | 99.03 | 111.44 | 162.12 | |
Capital Expenditures |
(0.69) | (0.60) | (0.85) | (0.68) | |
Net Current Asset Value |
112.19 | 75.55 | 89.72 | 141.38 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
55.11 | 73.20 | 63.50 | 60.01 | |
Average Payables |
29.34 | 35.39 | 34.86 | 34.68 | |
Average Assets |
606.34 | 560.88 | 640.72 | 647.66 | |
Average Common Equity |
341.55 | 324.92 | 337.75 | 360.22 |
Columns are period end dates